title: Female puberty: clinical implications for the use of prolactin-modulating psychotropics.
abstract: During puberty, girls may present with psychiatric illness necessitating treatment with psychotropic medications. Pubertal girls are especially vulnerable to medication-associated adverse events. Atypical antipsychotics and antidepressants have the potential to elevate prolactin levels, altering pubertal progression. Selection of prolactin-sparing atypical antipsychotics is recommended, as is treatment with the lowest effective dose of selective serotonin reuptake inhibitors. Monitoring of serum prolactin levels may be necessary.
authors.affiliation: Yale University School of Medicine, Child Study Center, 230 South Frontage Road, New Haven, CT 06520, USA. alb1655@aol.com
authors.forename: Amy L
authors.initials: AL
authors.lastname: Becker
authors.forename: C Neill
authors.initials: CN
authors.lastname: Epperson
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D005260:Female; D006058:Gonadal Disorders / Q000139:chemically induced; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D001523:Mental Disorders / Q000188:drug therapy*; D010913:Pituitary-Adrenal System / Q000187:drug effects; D011388:Prolactin / Q000378:metabolism*; D011627:Puberty / Q000502:physiology*
chemical_list: D014150:Antipsychotic Agents; D011388:Prolactin